Usefulness and performance evaluation of serum KL-6 and SP-A assays in healthy individuals and patients with interstitial lung disease

Background: Interstitial lung abnormalities (ILAs) are associated with the risk of progression to interstitial lung diseases (ILDs). Krebs von den Lungen 6 (KL-6) and surfactant protein (SP)-A have been used as biomarkers of ILDs. In this study, we evaluated the levels of these biomarkers and identified their clinical correlations in healthy individuals to assess their usefulness in the diagnosis of ILAs.Methods: The patient samples were categorized into three groups: healthy, disease, and ILD groups. We used the automated immunoassay HISCL KL-6 and SP-A assay kits. The analytical performance evaluation involved precision, linearity, comparison, establishment of reference intervals, and determination of the cutoff points. We also analyzed the correlations between presence of abnormalities on chest radiography and computed tomog-raphy (CT) or pulmonary function test (PFT) and serum levels in the healthy group.Results: KL-6 and SP-A assays showed good analytical performance. The KL-6 and SP-A cutoff values were 304 U/ mL and 43.5 ng/mL between the ILD and healthy groups, respectively, which were lower than the values rec-ommended by the manufacturer. In the clinical correlations with radiological findings, SP-A values in subjects with lung abnormalities on CT scans were significantly higher than those in normal scans. There was no sig-nificant difference in KL-6 and SP-A levels among PFT patterns; however, both serum levels in the mixed pattern showed higher values than those in the other patterns.Conclusions: The results revealed a positive association between increased serum levels of SP-A and KL-6 and clinical characteristics as incidental findings on chest imaging and reduced lung function.

Automated summary

This study evaluated the levels of KL-6 and SP-A in healthy individuals and their usefulness in diagnosing ILAs. The results showed a positive association between increased SP-A levels and abnormal CT scans, as well as higher levels of both biomarkers in the mixed pulmonary function test pattern.